First Eagle Investment Management LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,444,981 shares of the biopharmaceutical company’s stock after selling 949,334 shares during the quarter. First Eagle Investment Management LLC owned approximately 4.54% of Halozyme Therapeutics worth $111,949,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Teacher Retirement System of Texas acquired a new position in shares of Halozyme Therapeutics during the second quarter valued at $129,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Halozyme Therapeutics during the second quarter valued at $131,000. Prudential Financial Inc. boosted its holdings in shares of Halozyme Therapeutics by 8.7% during the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 940 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Halozyme Therapeutics during the second quarter valued at $171,000. Finally, Amalgamated Bank boosted its holdings in shares of Halozyme Therapeutics by 5.3% during the second quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 705 shares during the period. 83.28% of the stock is owned by hedge funds and other institutional investors.
Shares of Halozyme Therapeutics, Inc. (HALO) traded up $0.21 during midday trading on Tuesday, hitting $18.39. 1,030,400 shares of the company were exchanged, compared to its average volume of 1,424,803. Halozyme Therapeutics, Inc. has a fifty-two week low of $9.68 and a fifty-two week high of $19.37. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The company had revenue of $63.73 million for the quarter, compared to the consensus estimate of $58.95 million. During the same quarter in the prior year, the firm earned ($0.23) earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 100.1% compared to the same quarter last year. analysts predict that Halozyme Therapeutics, Inc. will post 0.09 earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on HALO shares. Canaccord Genuity set a $16.00 price target on shares of Halozyme Therapeutics and gave the company a “buy” rating in a report on Wednesday, July 26th. Jefferies Group LLC reissued an “underperform” rating and set a $7.00 price target (up previously from $6.75) on shares of Halozyme Therapeutics in a report on Thursday, August 10th. Piper Jaffray Companies set a $20.00 price target on shares of Halozyme Therapeutics and gave the company a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Friday, August 11th. Finally, BidaskClub downgraded shares of Halozyme Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $17.75.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.